Sign in
Download Opera News App

Health-COVID

Analysis: Sales of first big COVID-19 drug, remdesivir, may disappoint

Analysis: Sales of first big COVID-19 drug, remdesivir, may disappoint

(Reuters) - Investors betting on big profits from COVID-19 treatments may get an unwelcome surprise when Gilead Sciences Inc reports quarterly results this month. Its remdesivir, the first important coronavirus treatment, has not been used as much as first expected and faces complex insurance reimbursement issues. Its best hope may be that the United States and other Northern Hemisphere governments concerned about...

Read Full Story
COVID-19 Gilead Northern Hemisphere U.S. Food and Drug Administration United States WHO

Top News

US-politics

Senate Deal Delays Trump Trial, Clears Way for Biden Nominees

bloomberg.com
Senate Deal Delays Trump Trial, Clears Way for Biden Nominees

US-politics

Senate Deal Delays Trump Trial, Clears Way for Biden Nominees

bloomberg.com

Gossip-Celebrity

Nancy Grace mourns friend Larry King, ‘there’s never been anybody like him’

foxnews.com
Nancy Grace mourns friend Larry King, ‘there’s never been anybody like him’

Gossip-Celebrity

Nancy Grace mourns friend Larry King, ‘there’s never been anybody like him’

foxnews.com